Pfenex awards Paragon contract for cGMP manufacturing of anthrax vaccine

Pfenex, Inc., a San Diego-based biotechnology company, announced on Tuesday that it awarded Paragon Bioservices, Inc., a contract for the current good manufacturing practice manufacturing of its recombinant protective antigen anthrax vaccine.

Paragon, a contract research and manufacturing organization, will implement the cGMP-ready Pfenex Expression Technology-based production process for a Phase I clinical trial of the anthrax vaccine candidate. The funding will be provided through the Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

"We are pleased to award this contract to Paragon Bioservices," Bertrand Liang, the CEO of Pfenex, said. "This is the next step in reaching our common objective with BARDA to develop an anthrax vaccine with a product capable of achieving the goals of the Strategic National Stockpile for the U.S. government, including cost, shelf life, and administration improvements. With Paragon Bioservices we believe we will rapidly implement the large-scale cGMP production of the rPA required for our Phase I clinical trial."

Pfenex uses its core technology, Pfenex Expression Technology, in the expression of recombinant proteins for the rapid development of therapeutics. Paragon Bioservices focuses on the production of biopharmaceuticals and reagent-grade proteins for clinical use.

"My team and I are dedicated to providing manufacturing support to Pfenex, using their powerful protein expression technology," Marco Chacon, the CEO of Paragon, said. "This project becomes all the more important since it will enrich the national armamentarium of vaccines against potential bio weapons."